Postmarketing Studies
After approving a drug, FDA can require more studies: on safety, in children, or to confirm a benefit for drugs approved early. Companies also commit to some voluntarily. This is every one FDA tracks, with whether it is on time.
2,576 studies FDA required, or companies committed to, after approving a drug or biologic: 2,138 still open, 658 of them marked delayed by FDA.
- Open: 2,138
- Delayed: 658
- Past their final report date: 377
- Open confirmatory trials: 112, for accelerated approvals
Where open studies stand
FDA's status for each open study. Click one to filter the table.
- 658
- 610
- 591
- 279
What FDA asked for
Open studies by type.
- 914
- 668
- 420
- 112
- 24
Most delayed studies
Companies with the most studies FDA marks delayed.
- 29
- 24
- 24
- 22
- 20
Every study
Delayed first, then by due date; each product opens its application2,576 studies
| What FDA asked for | ||||
|---|---|---|---|---|
| Kinlytic (urokinase)BLA 21846 ยท Microbix Biosystems Inc. | Commitment | PMC 187-7: To conduct a study to assess the immunogenicity of Urokinase after primary dosing. Abbott will agree on a study design with CBER prior to initiating the study. | Delayed | Dec 31, 2004 |
| Zanaflex (tizanidine hydrochloride)NDA 21447 ยท Legacy Pharma Inc Sezc | Pediatric study (PREA) | PMR 1739-1: Deferred pediatric study of tizanidine for acute treatment of spasticity in pediatric patients ages 0 to 16. | Delayed | Dec 31, 2005 |
| Zegerid (omeprazole and sodium bicarbonate)NDA 21636 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 810-2: Single and multiple-dose pharmacokinetics (PK), pharmacodynamics (PD) and safety study in pediatric patients aged 12 to 16 years. | Delayed | Jul 15, 2007 |
| Zegerid (omeprazole and sodium bicarbonate)NDA 21636 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 810-1: Single and multiple-dose pharmacokinetics (PK), pharmacodynamics (PD) and safety study in pediatric patients aged 2 to 11 years. | Delayed | Jul 15, 2007 |
| Nexium (esomeprazole magnesium)NDA 21957 ยท AstraZeneca Pharmaceuticals LP | Pediatric study (PREA) | PMR 59-1: Deferred pediatric study under PREA for the treatment of Gastroesophageal Reflux Disease (GERD): Healing of Erosive Esophagitis, Maintenance of Healing of Erosive Esophagitis, Symptomatic Gastroesophagealโฆ | Delayed | Jun 30, 2008 |
| Oraqix (lidocaine and prilocaine)NDA 21451 ยท Dentsply Pharmaceutical | Pediatric study (PREA) | PMR 1440-2: We are deferring pediatric studies for ages 6-17 years for this application. | Delayed | Dec 19, 2008 |
| Zegerid (omeprazole and sodium bicarbonate)NDA 21706 ยท Santarus Inc | Pediatric study (PREA) | PMR 1584-1: Deferred pediatric study under PREA for the treatment or prevention of upper gastrointestinal bleeding in critically ill pediatric patients ages 2 to 11 years old and 12 to 16 years old. | Delayed | Dec 26, 2008 |
| Zegerid (omeprazole and sodium bicarbonate)NDA 21636 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1584-1: Deferred pediatric study under PREA for the treatment or prevention of upper gastrointestinal bleeding in critically ill pediatric patients ages 2 to 11 years old and 12 to 16 years old. | Delayed | Dec 26, 2008 |
| Cleviprex (clevidipine butyrate)NDA 22156 ยท Chiesi USA Inc | Pediatric study (PREA) | PMR 1258-1: Deferred pediatric studies under PREA for the reduction of blood pressure in pediatric patients ages 1 to 16 years old. | Delayed | Aug 1, 2011 |
| Nexiclon XR (clonidine)NDA 22499 ยท Tris Pharma Inc | Commitment | PMC 1579-2: You will perform a "Thorough QT Study" as described in ICH E14. This study can utilize your extended release formulation or an immediate release formulation. It can utilize a single 0.6 mg dose group and aโฆ | Delayed | Dec 3, 2011 |
| Nexiclon XR (clonidine)NDA 22499 ยท Tris Pharma Inc | Pediatric study (PREA) | PMR 1579-1: Deferred pediatric study under PREA for the treatment of hypertension in pediatric patients ages 1 to 18. | Delayed | Dec 3, 2011 |
| Apriso (mesalamine)NDA 22301 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1464-1: Deferred pediatric study under PREA for the maintenance of remission of ulcerative colitis in pediatric patients ages 5 to 17 years to evaluate safety, effectiveness, and pharmacokinetics with Aprisoโฆ | Delayed | Jun 1, 2013 |
| Phoslyra (calcium acetate)NDA 22581 ยท Fresenius Medical Care Renal Therapies Group LLC | Commitment | PMC 1755-2: A multi-phase clinical trial in a hyperphosphatemic pediatric dialysis population, with a placebo-controlled dose-response phase, followed by an open-label titration and maintenance phase, followed by aโฆ | Delayed | Mar 31, 2014 |
| Oravig (miconazole)NDA 22404 ยท Galt Pharmaceuticals LLC | Pediatric study (PREA) | PMR 1635-1: Deferred pediatric study under PREA investigating ORAVIG safety, pharmacokinetics, efficacy and compliance with use instructions in patients with oropharyngeal candidiasis ages > 5 to < or = 17 years. | Delayed | Mar 31, 2014 |
| Sprix (ketorolac tromethamine)NDA 22382 ยท Cosette Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1551-2: An open label pharmacokinetic and safety study of SPRIX in pediatric patients ages 12 to less than 17 years of age | Delayed | May 31, 2014 |
| Advil (ibuprofen sodium)NDA 201803 ยท Haleon US Holdings LLC | Pediatric study (PREA) | PMR 1905-1: The applicant currently proposes to develop a liquid pediatric formulation and then perform a pharmacokinetic (PK) study in adults comparing the pediatric formulation to an approved pediatric ibuprofenโฆ | Delayed | Jun 30, 2014 |
| Adasuve (loxapine)NDA 22549 ยท Nova Pneuma Inc | Safety study (FDAAA) | PMR 1891-4: Conduct a large, non-randomized, open-label, postmarketing observational study to assess the risks of bronchospasm and related respiratory adverse events and serious outcomes (e.g., hospitalization,โฆ | Delayed | Dec 1, 2015 |
| Dilaudid and Dilaudid-HP (hydromorphone hydrochloride)NDA 19034 ยท Fresenius Kabi USA LLC | Pediatric study (PREA) | PMR 347-1: Deferred pediatric study under PREA for the management of pain in patients where an opioid analgesic is appropriate in pediatric patients ages 0 to 16 years. | Delayed | Dec 31, 2015 |
| Beleodaq (belinostat)NDA 206256 ยท Acrotech Biopharma Inc | Safety study (FDAAA) | PMR 2178-6: Evaluate the safety and pharmacokinetics of belinostat in patients with wild-type, heterozygous, and homozygous UGT1A1*28 genotypes. The evaluations should be conducted for sufficient duration and in aโฆ | Delayed | Mar 31, 2016 |
| Oxaydo (oxycodone hydrochloride)NDA 202080 ยท Zyla Life Sciences US Inc | Safety study (FDAAA) | PMR 1793-1: An epidemiological study to address whether this formulation of Oxycodone HCl results in a decrease in misuse and abuse, and their consequences: overdose, death and addiction. | Delayed | Jun 30, 2016 |
| Zipsor (diclofenac potassium)NDA 22202 ยท Cosette Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1053-2: Deferred pediatric study under PREA for the treatment of relief of mild to moderate acute pain in pediatric patients ages 2 to 12 years. | Delayed | Jun 30, 2016 |
| Uceris (budesonide)NDA 203634 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1997-1: An 8-week randomized, double blind, placebo-controlled trial in children 5 to 17 years of age with active, mild to moderate ulcerative colitis. The trial will evaluate pharmacokinetics (PK), efficacy forโฆ | Delayed | Sep 30, 2016 |
| Oxtellar XR (oxcarbazepine)NDA 202810 ยท Supernus Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1938-4: A clinical trial to examine pharmacokinetics and tolerability in children, ages 1 month to 6 months, using an age appropriate extended release oxcarbazepine formulation. | Delayed | Dec 31, 2016 |
| Oxtellar XR (oxcarbazepine)NDA 202810 ยท Supernus Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1938-3: A clinical trial to examine pharmacokinetics and tolerability in children ages 6 months to 4 years using an age appropriate extended release oxcarbazepine formulation. | Delayed | Dec 31, 2016 |
| LaVivBLA 125348 ยท Fibrocell Technologies, Inc. | Safety study (FDAAA) | Conduct a study, based on a registry design, to assess the risk of skin cancer in the area of azficel-T injections and the risk of immune-mediated hypersensitivity reactions in 2700 patients who receive azficel-T. | Delayed | Dec 31, 2016 |
| GINTUITBLA 125400 ยท Organogenesis, Inc. | Pediatric study (PREA) | Assess the safety and effectiveness of Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen for topical (non-submerged) application to a surgically created vascular wound bed in the treatment ofโฆ | Delayed | Mar 31, 2017 |
| Zorvolex (diclofenac)NDA 204592 ยท Zyla Life Sciences US Inc | Pediatric study (PREA) | PMR 2091-1: An open-label pharmacokinetic and safety study or studies of an ageappropriate formulation of Zorvolex in pediatric patients 6 years to less than 17 years of age with acute pain. | Delayed | May 3, 2017 |
| Myobloc (RimabotulinumtoxinB)BLA 103846 ยท Solstice NeuroSciences, LLC | Commitment | PMC 2324-10: Randomized,-double-blind, adequately controlled, multiple fixed doses, parallel group clinical trials of Myobloc (botulinum toxin Type B) in the following populations: botulinum toxin-naive children ageโฆ | Delayed | May 31, 2017 |
| Aralast; Aralast NPBLA 125039 ยท Takeda Pharmaceuticals U.S.A., Inc. | Commitment | Conduct and report the results of a pilot trial to determine the effect of regular administration of the product on one or more clinically meaningful endpoint(s). Examples of acceptable endpoints include pulmonaryโฆ | Delayed | Jul 31, 2017 |
| Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate)NDA 22372 ยท Azurity Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1580-4: Conduct a randomized, single-blind, multicenter dose ranging study comparing the safety and efficacy of SUPREP to NuLytely in children (3 years to 11 years). | Delayed | Nov 30, 2017 |
| Zorvolex (diclofenac)NDA 204592 ยท Zyla Life Sciences US Inc | Pediatric study (PREA) | PMR 2091-2: An open-label pharmacokinetic and safety study or studies of an ageappropriate formulation of Zorvolex in pediatric patients 2 years to less than 6 years of age with acute pain. | Delayed | Jan 6, 2018 |
| Uceris (budesonide)NDA 205613 ยท Salix Pharmaceuticals Inc | Commitment | PMC 2800-1: A 6-week randomized, double blind, placebo-controlled trial in children 5 to 17 years of age with active, mild to moderate distal ulcerative colitis (extending up to 40 cm from the anal verge). The trialโฆ | Delayed | Apr 30, 2018 |
| Treximet (naproxen sodium and sumatriptan)NDA 21926 ยท Azurity Pharmaceuticals Inc | Pediatric study (PREA) | PMR 2910-1: Conduct a juvenile rat toxicology study to identify the unexpected serious risk of adverse effects of sumatriptan/naproxen on postnatal growth and development. The study should utilize animals of an ageโฆ | Delayed | May 31, 2018 |
| Treximet (naproxen sodium and sumatriptan)NDA 21926 ยท Azurity Pharmaceuticals Inc | Pediatric study (PREA) | PMR 2910-1: Conduct a juvenile rat toxicology study to identify the unexpected serious risk of adverse effects of sumatriptan/naproxen on postnatal growth and development. The study should utilize animals of an ageโฆ | Delayed | May 31, 2018 |
| TalcNDA 21388 ยท Sciarra Laboratories Inc | Safety study (FDAAA) | PMR 3332-1: Perform a risk assessment study on the lead content of sterile talc powder and indicate any necessary controls on elemental impurities as per ICH Q3D Elemental Impurities: Guidance for Industry. | Delayed | May 31, 2018 |
| Sclerosol Intrapleural Aerosol (talc)NDA 20587 ยท Sciarra Laboratories Inc | Safety study (FDAAA) | PMR 3325-1: Perform a risk assessment study on the lead content of sterile talc powder and indicate any necessary controls on elemental impurities as per ICH Q3D Elemental Impurities: Guidance for Industry. | Delayed | May 31, 2018 |
| Diclegis (doxylamine succinate and pyridoxine hydrochloride)NDA 21876 ยท Duchesnay Inc | Pediatric study (PREA) | PMR 2033-1: An adequately powered safety and efficacy study in pregnant adolescent girls, 12 to 17 years of age, with nausea and vomiting of pregnancy who are appropriate candidates for pharmacologic therapy. | Delayed | Jul 31, 2018 |
| Xifaxan (rifaximin)NDA 21361 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 858-1: Deferred pediatric studies under PREA for the treatment of traveler's diarrhea in pediatric patients ages 3 years to 12 years. Final Report Submission: May 1, 2009. | Delayed | Jul 31, 2018 |
| Probuphine (buprenorphine)NDA 204442 ยท Reacx Pharmaceuticals Inc | Safety study (FDAAA) | PMR 3078-4: Clinical trial to evaluate the safety, feasibility, and pharmacokinetics of PROBUPHINE (buprenorphine hydrochloride) implantation at alternate body sites. The trial should also evaluate the safety of otherโฆ | Delayed | Aug 31, 2018 |
| GlassiaBLA 125325 ยท Takeda Pharmaceuticals U.S.A., Inc. | Commitment | Kamada Ltd. commits to conduct and report the results of a Human Factors study, to evaluate the types of problems that patients/caregivers may encounter in self-infusing. This information will be used to revise, asโฆ | Delayed | Aug 31, 2018 |
| Hemlibra (emicizumab-kxwh)BLA 761083 ยท Genentech, Inc. | Commitment | PMC 3299-1: Conduct an assessment of binding anti-product antibody (APA) responses with a validated assay capable of sensitively detecting APA responses in the presence of emicizumab levels that are expected to beโฆ | Delayed | Jan 31, 2019 |
| Aplenzin (bupropion hydrobromide)NDA 22108 ยท Bausch Health US LLC | Pediatric study (PREA) | PMR 133-1: Deferred pediatric study under PREA for the treatment of Major Depressive Disorder in pediatric patients ages 7 to 17. | Delayed | Feb 28, 2019 |
| Xifaxan (rifaximin)NDA 21361 ยท Salix Pharmaceuticals Inc | Pediatric study (PREA) | PMR 2900-1: Conduct a pharmacokinetic, pharmacodynamics, tolerability and dose ranging study in subjects 6 years through 17 years, to assess safety and to determine the doses to be used in the efficacy study.โฆ | Delayed | Mar 31, 2019 |
| Myobloc (RimabotulinumtoxinB)BLA 103846 ยท Solstice NeuroSciences, LLC | Safety study (FDAAA) | PMR 2324-9: Submit safety data assessing distant spread of toxin effects after multiple administrations off Myobloc (botulinum toxin Type B), during a minimum period of 12 months, collected in at least 100 pediatricโฆ | Delayed | Mar 31, 2019 |
| Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate)NDA 22372 ยท Azurity Pharmaceuticals Inc | Pediatric study (PREA) | PMR 1580-9: Conduct a randomized, single-blind, multicenter dose ranging study comparing the safety and efficacy of SUPREP to NuLytely in children (6 months to 2 years). | Delayed | May 31, 2019 |
| Siliq (brodalumab)BLA 761032 ยท Bausch Health Ireland, Limited | Pediatric study (PREA) | PMR 3164-1: Open-label study to determine PK of a single dose of brodalumab in 16 children (6 to < 18 years old) with severe plaque psoriasis. | Delayed | Jun 30, 2019 |
| Probuphine (buprenorphine)NDA 204442 ยท Reacx Pharmaceuticals Inc | Safety study (FDAAA) | PMR 3078-3: Clinical trial to evaluate the effect of scarring or inflammation related to a prior implant on the safety of re-implantation/reinsertion, the potential for migration of implants, and the bioavailability ofโฆ | Delayed | Aug 31, 2019 |
| Xtampza ER (oxycodone)NDA 208090 ยท Collegium Pharmaceutical Inc | Safety study (FDAAA) | PMR 3033-11: Conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of high-dose ER/LA opioid analgesics for at least one year to treat chronic pain.โฆ | Delayed | Aug 31, 2019 |
| Belbuca (buprenorphine hydrochloride)NDA 207932 ยท Biodelivery Sciences International Inc | Safety study (FDAAA) | PMR 3033-11: Conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of high-dose ER/LA opioid analgesics for at least one year to treat chronic pain.โฆ | Delayed | Aug 31, 2019 |
| Hysingla ER (hydrocodone bitartrate)NDA 206627 ยท Knoa Pharma LLC | Safety study (FDAAA) | PMR 3033-11: Conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of high-dose ER/LA opioid analgesics for at least one year to treat chronic pain.โฆ | Delayed | Aug 31, 2019 |
Requirements (PMRs) are studies FDA can compel: safety studies under FDAAA, pediatric studies under PREA, and confirmatory trials for accelerated approvals. Commitments (PMCs) are studies a company agreed to. FDA's file lists open studies and those closed in roughly the last year, with FDA's own status; โpast dueโ means the original final report date has passed and FDA has not recorded the report as submitted. Refreshed weekly, last Nov 16, 2026. FDA, Postmarketing Requirements and Commitments database file